ClinicalTrials.Veeva

Menu

Lung Cancer Screening Eligibility Assessment

Abramson Cancer Center at Penn Medicine logo

Abramson Cancer Center at Penn Medicine

Status

Completed

Conditions

Lung Cancer

Treatments

Behavioral: Framed Introductory Message A
Behavioral: Framed Tobacco Use Message B
Behavioral: Framed Tobacco Use Message A
Behavioral: Financial Incentive
Behavioral: Framed Introductory Message C
Behavioral: Framed Introductory Message B

Study type

Interventional

Funder types

Other
NIH

Identifiers

NCT06133816
853337 (Other Identifier)
UPCC 16523
P50CA271338-02 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

The primary purpose of this study evaluate if different messaging impacts response rates to a brief survey (i.e., the simplified eligibility tool) that is designed to estimate pack-year eligibility for lung cancer screening (LCS). This will help inform the best way to increase response rates to the tool in future intervention studies designed to increase LCS, and expand upon survey methodology in general.

Full description

Despite growing evidence that lung cancer screening (LCS) reduces lung cancer-specific mortality, LCS across the United States is remarkably low. This is due in part to challenges with identifying adults who meet eligibility criteria for lifetime smoking intensity (i.e., 20 pack-years or greater), which is often missing from the electronic medical record. We have developed a simplified eligibility tool that has shown accuracy in estimating pack-years. But given the potential for low response rates, there is a great need to identify effective strategies to increasing response rates equitably prior to using it in practice or in future studies. The primary purpose of this study evaluate if different messaging impacts response rates to a brief survey (i.e., the simplified eligibility tool) that is designed to estimate pack-year eligibility for lung cancer screening (LCS). This will help to identify the best way to increase response rates to the tool in future intervention studies designed to increase LCS, and expand upon survey methodology in general.

Enrollment

6,125 patients

Sex

All

Ages

50 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. meet age eligibility (50-80 years old) for LCS based on 2021 USPSTF guidelines; and
  2. have completed at least one primary care visit at Penn Medicine in 2020-2025

Exclusion criteria

  1. have a documented history of lung cancer;
  2. have a documented history of completing LCS at Penn Medicine;
  3. are listed as not wanting to be contacted or solicited for research; or
  4. do not otherwise meet inclusion criteria.

Trial design

Primary purpose

Health Services Research

Allocation

Randomized

Interventional model

Factorial Assignment

Masking

Single Blind

6,125 participants in 12 patient groups

Arm 1 (Introductory Message A + Tobacco Use Message A + Incentive)
Experimental group
Description:
Participants will receive two framed messages (AA) plus an incentive
Treatment:
Behavioral: Financial Incentive
Behavioral: Framed Tobacco Use Message A
Behavioral: Framed Introductory Message A
Arm 2 (Introductory Message A + Tobacco Use Message A)
Experimental group
Description:
Participants will receive two framed messages (AA)
Treatment:
Behavioral: Framed Tobacco Use Message A
Behavioral: Framed Introductory Message A
Arm 3 (Introductory Message A + Tobacco Use Message B + Incentive)
Experimental group
Description:
Participants will receive two framed messages (AB) plus an incentive
Treatment:
Behavioral: Financial Incentive
Behavioral: Framed Tobacco Use Message B
Behavioral: Framed Introductory Message A
Arm 4 (Introductory Message A + Tobacco Use Message B)
Experimental group
Description:
Participants will receive two framed messages (AB)
Treatment:
Behavioral: Framed Tobacco Use Message B
Behavioral: Framed Introductory Message A
Arm 5 (Introductory Message B + Tobacco Use Message A + Incentive)
Experimental group
Description:
Participants will receive two framed messages (BA) plus an incentive
Treatment:
Behavioral: Financial Incentive
Behavioral: Framed Introductory Message B
Behavioral: Framed Tobacco Use Message A
Arm 6 (Introductory Message B + Tobacco Use Message A)
Experimental group
Description:
Participants will receive two framed messages (BA)
Treatment:
Behavioral: Framed Introductory Message B
Behavioral: Framed Tobacco Use Message A
Arm 7 (Introductory Message B + Tobacco Use Message B + Incentive)
Experimental group
Description:
Participants will receive two framed messages (BB) plus an incentive
Treatment:
Behavioral: Financial Incentive
Behavioral: Framed Introductory Message B
Behavioral: Framed Tobacco Use Message B
Arm 8 (Introductory Message B + Tobacco Use Message B)
Experimental group
Description:
Participants will receive two framed messages (BB)
Treatment:
Behavioral: Framed Introductory Message B
Behavioral: Framed Tobacco Use Message B
Arm 9 (Introductory Message C + Tobacco Use Message A + Incentive)
Experimental group
Description:
Participants will receive two framed messages (CA) plus an incentive
Treatment:
Behavioral: Financial Incentive
Behavioral: Framed Introductory Message C
Behavioral: Framed Tobacco Use Message A
Arm 10 (Introductory Message C + Tobacco Use Message A)
Experimental group
Description:
Participants will receive two framed message (CA)
Treatment:
Behavioral: Framed Introductory Message C
Behavioral: Framed Tobacco Use Message A
Arm 11 (Introductory Message C + Tobacco Use Message B + Incentive)
Experimental group
Description:
Participants will receive two framed messages (CB) plus an incentive
Treatment:
Behavioral: Financial Incentive
Behavioral: Framed Introductory Message C
Behavioral: Framed Tobacco Use Message B
Arm 12 (Introductory Message C + Tobacco Use Message B)
Experimental group
Description:
Participants will receive two framed messages (CB)
Treatment:
Behavioral: Framed Introductory Message C
Behavioral: Framed Tobacco Use Message B

Trial documents
2

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems